About me
Dr. Ezzeldin is the Associate Director for Advanced Technologies in the Office of Biostatistics and Pharmacovigilance (OBPV), in the Center for Biologics Evaluation and Research (CBER). Dr. Ezzeldin supported multiple programs in previous roles, for example, leading the digital health technology review team, and leading the natural history study for metachromatic leukodystrophy, HOME, among other initiatives. Currently, Dr. Ezzeldin leads the Biologics Effectiveness and Safety Innovative Methods Initiative (BEST IM), which aims to develop new and innovative methods for a semi-automated adverse events (AEs) reporting system for CBER-Regulated Biological Products. Also, Dr. Ezzeldin is involved in RWD/RWE/DHT and AI policy initiatives.
